Gregory Mattingly is a Psychiatry physician. OpenAlex indexes 84 publications with 2,609 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 1st Capitol Dr
Ste 390
Saint Charles, MO 633012852
Telephone
636-949-5760Registry record last updated 26 Jan 2017.
Industry payments
49 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Axsome Therapeutics, Inc.Program year2025123 payments$172,023openpaymentsdata.cms.gov ↗
- Neurocrine BioSciences, Inc.Program year2025101 payments$130,424openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year2025113 payments$120,029openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97.9%Benzodiazepine26%Alprazolam36%Clonazepam23%Lorazepam22%Temazepam10%Diazepam6%Triazolam3%Ativan1%Part D<11 patientsSSRI15.3%Trazodone Hcl29%Escitalopram Oxalate21%Sertraline Hcl16%Fluoxetine Hcl15%Citalopram Hbr10%Paroxetine Hcl8%Fluvoxamine Maleate2%Part D<11 patients+ 25 more classes in this area
Cardiovascular
1.2%Beta blocker0.6%Propranolol Hcl59%Metoprolol Succinate41%Part D<11 patientsCentral alpha-2 Adrenergic Agonist0.6%Clonidine Hcl100%Part D<11 patientsHormonal (systemic)
0.3%l-Thyroxine0.3%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
Neuropsychiatric Disease and Treatment
2025 - 52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity Disorder
Journal of Clinical Psychopharmacology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”